Shota Murata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shota Murata has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Akiko Suganami
Department of Bioinformatics, Graduate School of Medicine, Chiba University, Chiba, Japan
1 shared publication- Eiji Ido
Department of Infectious Diseases, Chiba University Hospital, Chiba, Japan
1 shared publication - Hidetoshi Igari
Department of Infectious Diseases, Chiba University Hospital, Chiba, Japan
1 shared publication - Kazuyuki Matsushita
Department of Laboratory Medicine, Chiba University Hospital, Chiba 260-8677, Japan
1 shared publication Kengo Saito
Department of Molecular Virology, Graduate School of Medicine, Chiba University, Chiba, Japan
1 shared publicationMisuzu Yahaba
Department of Infectious Diseases, Chiba University Hospital, Chiba, Japan
1 shared publication
Latest Publications
- Open Access
- 29 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Dynamic diversity of SARS-CoV-2 genetic mutations in a lung transplantation patient with persistent COVID-19
Numerous SARS-CoV-2 variant strains with altered characteristics have emerged since the onset of the COVID-19 pandemic. Remdesivir (RDV), a ribonucleotide analogue inhibitor of viral RNA polymerase, has become a valuable therapeutic agent. However, immunosuppressed hosts may respond inadequately to RDV and develop chronic persistent infections. A patient with respiratory failure caused by interstitial pneumonia, who had undergone transplantation of the left lung, developed COVID-19 caused by Omicron BA.5 strain with persistent chronic viral shedding, showing viral fusogenicity. Genome-wide sequencing analyses revealed the occurrence of several viral mutations after RDV treatment, followed by dynamic changes in the viral populations. The C799F mutation in nsp12 was found to play a pivotal role in conferring RDV resistance, preventing RDV-triphosphate from entering the active site of RNA-dependent RNA polymerase. The occurrence of diverse mutations is a characteristic of SARS-CoV-2, which mutates frequently. Herein, we describe the clinical case of an immunosuppressed host in whom inadequate treatment resulted in highly diverse SARS-CoV-2 mutations that threatened the patient’s health due to the development of drug-resistant variants.
- 29 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Open AccessDynamic diversity of SARS-CoV-2 genetic mutations in a lung transplantation patient with persistent COVID-19
Numerous SARS-CoV-2 variant strains with altered characteristics have emerged since the onset of the COVID-19 pandemic. Remdesivir (RDV), a ribonucleotide analogue inhibitor of viral RNA polymerase, has become a valuable therapeutic agent. However, immunosuppressed hosts may respond inadequately to RDV and develop chronic persistent infections. A patient with respiratory failure caused by interstitial pneumonia, who had undergone transplantation of the left lung, developed COVID-19 caused by Omicron BA.5 strain with persistent chronic viral shedding, showing viral fusogenicity. Genome-wide sequencing analyses revealed the occurrence of several viral mutations after RDV treatment, followed by dynamic changes in the viral populations. The C799F mutation in nsp12 was found to play a pivotal role in conferring RDV resistance, preventing RDV-triphosphate from entering the active site of RNA-dependent RNA polymerase. The occurrence of diverse mutations is a characteristic of SARS-CoV-2, which mutates frequently. Herein, we describe the clinical case of an immunosuppressed host in whom inadequate treatment resulted in highly diverse SARS-CoV-2 mutations that threatened the patient’s health due to the development of drug-resistant variants.